On January 2, 2025, Joseph L. Goldstein, a key figure at Regeneron Pharmaceuticals, was granted 166 shares of Common Stock at $0 per share. This transaction was reported as a direct acquisition, classified under the transaction code 'A' for grant, award, or other acquisition.Following this transaction, Goldstein's direct ownership of Regeneron's Common Stock increased to 6,548 shares. The grant was completed on the reported date, with no additional transactions mentioned in the filing. This stock award appears to be part of Regeneron's executive compensation strategy, potentially aligning Goldstein's interests with those of the company's shareholders.

On January 2, 2025, Joseph L. Goldstein, a key figure at Regeneron Pharmaceuticals, was granted 166 shares of Common Stock at $0 per share. This transaction was reported as a direct acquisition, classified under the transaction code 'A' for grant, award, or other acquisition.Following this transaction, Goldstein's direct ownership of Regeneron's Common Stock increased to 6,548 shares. The grant was completed on the reported date, with no additional transactions mentioned in the filing. This stock award appears to be part of Regeneron's executive compensation strategy, potentially aligning Goldstein's interests with those of the company's shareholders.